Everpar Advisors
MRNA icon

Everpar Advisors’s Moderna MRNA Stock Holding History

Everpar Advisors’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$470K Buy
+2,443
New +$263K 0.13% 157

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $824B AUM 37.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $106B AUM 2.29% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $294B AUM 47.59% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.27T AUM 50.62% 1-Year Est. Return
Citigroup
Citigroup New York $308B AUM 40.94% 1-Year Est. Return

Everpar Advisors's MRNA Position: Q3 2026 in Review

Everpar Advisors opened a new position in Moderna (MRNA) in Q3 2026: 2,443 shares worth $470K. The stake represents 0.13% of the portfolio and ranks #157 among its holdings.

737 funds tracked by Wall St. Rank hold MRNA as of Q3 2026.

  • Everpar Advisors held 2,443 shares of Moderna worth $470K as of Q3 2026.
  • Moderna was a new Everpar Advisors position in Q3 2026.
  • Moderna made up 0.13% of Everpar Advisors's portfolio in Q3 2026, its #157 holding.
  • 737 funds tracked by Wall St. Rank held Moderna as of Q3 2026.

Based on Everpar Advisors's 13F filing for Q3 2026, filed 12 Nov 2026.